The primary objective is to estimate the average relative change from baseline in tumor uptake of [89Zr]Zr-BI 765063 upon treatment with BI 765063
Behandeling: Ezabenlimab, BI 754091
Dr. C.W. Menke-van der Houven van Oordt,
Amsterdam UMC, locatie VUmc, afdeling medische oncologie
De Boelelaan 1117
1081 HV Amsterdam
Telefoon: 020-4440522